| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Therapy | 28 | 2024 | 744 | 4.860 |
Why?
|
| Hematopoietic Stem Cells | 18 | 2019 | 273 | 3.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 19 | 2019 | 328 | 2.810 |
Why?
|
| Fanconi Anemia | 6 | 2018 | 15 | 1.900 |
Why?
|
| Developing Countries | 3 | 2024 | 84 | 1.840 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 86 | 1.480 |
Why?
|
| Transduction, Genetic | 7 | 2019 | 233 | 1.440 |
Why?
|
| Cell- and Tissue-Based Therapy | 3 | 2022 | 38 | 1.290 |
Why?
|
| Immunotherapy | 4 | 2020 | 235 | 1.270 |
Why?
|
| Neoplasms | 6 | 2022 | 1258 | 1.130 |
Why?
|
| Lentivirus | 8 | 2019 | 62 | 1.060 |
Why?
|
| Glioblastoma | 4 | 2014 | 156 | 0.930 |
Why?
|
| Brain Neoplasms | 5 | 2014 | 306 | 0.910 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 3 | 2018 | 5 | 0.860 |
Why?
|
| Genetic Vectors | 16 | 2019 | 820 | 0.810 |
Why?
|
| Stem Cells | 3 | 2023 | 257 | 0.760 |
Why?
|
| CRISPR-Cas Systems | 2 | 2023 | 330 | 0.760 |
Why?
|
| Gene Editing | 3 | 2023 | 301 | 0.750 |
Why?
|
| DNA Repair | 4 | 2007 | 233 | 0.750 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 332 | 0.710 |
Why?
|
| Science | 1 | 2021 | 34 | 0.710 |
Why?
|
| HMGA1a Protein | 4 | 2007 | 5 | 0.670 |
Why?
|
| Transplantation Conditioning | 4 | 2015 | 94 | 0.640 |
Why?
|
| Virus Integration | 6 | 2018 | 32 | 0.640 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2019 | 90 | 0.600 |
Why?
|
| Cell Separation | 2 | 2016 | 147 | 0.590 |
Why?
|
| Humans | 52 | 2024 | 59817 | 0.580 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 442 | 0.570 |
Why?
|
| HIV Infections | 2 | 2021 | 927 | 0.550 |
Why?
|
| Cyclophosphamide | 2 | 2018 | 71 | 0.550 |
Why?
|
| Automation, Laboratory | 1 | 2016 | 7 | 0.550 |
Why?
|
| Metal Nanoparticles | 1 | 2019 | 180 | 0.530 |
Why?
|
| Animals | 33 | 2022 | 19722 | 0.460 |
Why?
|
| Spumavirus | 3 | 2018 | 3 | 0.390 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 968 | 0.370 |
Why?
|
| Induced Pluripotent Stem Cells | 4 | 2015 | 136 | 0.360 |
Why?
|
| Macaca nemestrina | 6 | 2019 | 8 | 0.360 |
Why?
|
| Antigens, CD34 | 5 | 2019 | 53 | 0.340 |
Why?
|
| Alpha-Globulins | 1 | 2009 | 4 | 0.330 |
Why?
|
| Vitronectin | 1 | 2009 | 6 | 0.330 |
Why?
|
| Bronchi | 1 | 2009 | 77 | 0.320 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2007 | 4 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2018 | 14 | 0.280 |
Why?
|
| DNA Modification Methylases | 4 | 2015 | 18 | 0.270 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2018 | 43 | 0.270 |
Why?
|
| DNA Repair Enzymes | 4 | 2015 | 37 | 0.270 |
Why?
|
| X-Linked Combined Immunodeficiency Diseases | 2 | 2018 | 3 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 184 | 0.260 |
Why?
|
| Retroviridae | 3 | 2015 | 72 | 0.250 |
Why?
|
| High Mobility Group Proteins | 1 | 2005 | 18 | 0.250 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 356 | 0.250 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2015 | 194 | 0.250 |
Why?
|
| Transgenes | 4 | 2017 | 176 | 0.240 |
Why?
|
| Bone Marrow Cells | 3 | 2016 | 232 | 0.240 |
Why?
|
| Oligonucleotides | 2 | 2023 | 211 | 0.240 |
Why?
|
| Patient Advocacy | 1 | 2024 | 32 | 0.230 |
Why?
|
| HEK293 Cells | 3 | 2016 | 578 | 0.220 |
Why?
|
| Antigens, CD19 | 2 | 2022 | 20 | 0.220 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 61 | 0.220 |
Why?
|
| Cell Lineage | 4 | 2017 | 249 | 0.210 |
Why?
|
| Mice | 12 | 2022 | 10309 | 0.210 |
Why?
|
| Dacarbazine | 2 | 2014 | 20 | 0.210 |
Why?
|
| Hemophilia A | 1 | 2022 | 56 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 483 | 0.200 |
Why?
|
| Hemostatics | 1 | 2022 | 26 | 0.200 |
Why?
|
| DNA, Mitochondrial | 1 | 2023 | 78 | 0.200 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2012 | 31 | 0.190 |
Why?
|
| Chromatin | 2 | 2007 | 598 | 0.190 |
Why?
|
| Heterocyclic Compounds | 2 | 2018 | 12 | 0.180 |
Why?
|
| Myeloid Cells | 2 | 2019 | 92 | 0.180 |
Why?
|
| Fetal Hemoglobin | 1 | 2019 | 12 | 0.170 |
Why?
|
| Flow Cytometry | 3 | 2012 | 638 | 0.160 |
Why?
|
| Blood | 1 | 2019 | 27 | 0.160 |
Why?
|
| Electroporation | 1 | 2019 | 32 | 0.160 |
Why?
|
| RNA | 1 | 2023 | 405 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 661 | 0.160 |
Why?
|
| Autografts | 1 | 2018 | 7 | 0.150 |
Why?
|
| Genes, Viral | 1 | 2018 | 56 | 0.150 |
Why?
|
| Bone Marrow Transplantation | 1 | 2018 | 135 | 0.150 |
Why?
|
| Cell Differentiation | 5 | 2019 | 1297 | 0.150 |
Why?
|
| Endothelial Cells | 2 | 2016 | 176 | 0.150 |
Why?
|
| Dog Diseases | 1 | 2018 | 54 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2019 | 192 | 0.140 |
Why?
|
| Carmustine | 2 | 2014 | 10 | 0.140 |
Why?
|
| Guanine | 2 | 2014 | 22 | 0.140 |
Why?
|
| Base Sequence | 3 | 2009 | 1311 | 0.140 |
Why?
|
| Gold | 1 | 2019 | 227 | 0.140 |
Why?
|
| Mice, Inbred NOD | 5 | 2018 | 511 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2015 | 259 | 0.140 |
Why?
|
| Pyrimidine Dimers | 2 | 2007 | 2 | 0.140 |
Why?
|
| Virus Replication | 1 | 2018 | 306 | 0.140 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2007 | 54 | 0.130 |
Why?
|
| Genetic Engineering | 1 | 2017 | 112 | 0.130 |
Why?
|
| United States | 3 | 2021 | 7569 | 0.130 |
Why?
|
| Graft Survival | 1 | 2017 | 279 | 0.130 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 234 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 2016 | 125 | 0.130 |
Why?
|
| Astatine | 1 | 2015 | 1 | 0.130 |
Why?
|
| beta-Thalassemia | 1 | 2015 | 13 | 0.120 |
Why?
|
| Leukocyte Common Antigens | 1 | 2015 | 55 | 0.120 |
Why?
|
| Mitomycin | 2 | 2012 | 23 | 0.120 |
Why?
|
| DNA Damage | 2 | 2007 | 281 | 0.120 |
Why?
|
| Multipotent Stem Cells | 1 | 2015 | 12 | 0.120 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2015 | 52 | 0.120 |
Why?
|
| Societies | 1 | 2014 | 22 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 498 | 0.120 |
Why?
|
| Female | 7 | 2021 | 31100 | 0.120 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 2079 | 0.110 |
Why?
|
| Cell Line, Tumor | 3 | 2007 | 1379 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2012 | 1470 | 0.110 |
Why?
|
| Sirolimus | 1 | 2014 | 77 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2019 | 843 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 171 | 0.110 |
Why?
|
| Genome, Human | 1 | 2015 | 219 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2014 | 174 | 0.110 |
Why?
|
| Mice, Knockout | 3 | 2018 | 1997 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2018 | 1843 | 0.100 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 293 | 0.100 |
Why?
|
| HIV-1 | 1 | 2018 | 709 | 0.100 |
Why?
|
| Mice, SCID | 4 | 2015 | 506 | 0.100 |
Why?
|
| Cytogenetics | 1 | 2012 | 8 | 0.100 |
Why?
|
| Methylcellulose | 1 | 2012 | 4 | 0.100 |
Why?
|
| Myeloablative Agonists | 1 | 2012 | 13 | 0.100 |
Why?
|
| Heterografts | 3 | 2019 | 60 | 0.100 |
Why?
|
| Leadership | 1 | 2014 | 201 | 0.100 |
Why?
|
| Software | 1 | 2015 | 373 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2012 | 106 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2011 | 13 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 233 | 0.100 |
Why?
|
| Internet | 1 | 2015 | 460 | 0.090 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2011 | 1 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2014 | 250 | 0.090 |
Why?
|
| Biomarkers | 1 | 2016 | 1205 | 0.090 |
Why?
|
| Teratoma | 1 | 2011 | 11 | 0.090 |
Why?
|
| Cell Line | 3 | 2011 | 2015 | 0.090 |
Why?
|
| Genomics | 1 | 2014 | 314 | 0.090 |
Why?
|
| Male | 6 | 2018 | 27771 | 0.090 |
Why?
|
| Cellular Reprogramming | 1 | 2011 | 33 | 0.090 |
Why?
|
| Linoleic Acid | 1 | 2010 | 18 | 0.090 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2010 | 24 | 0.090 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2010 | 4 | 0.090 |
Why?
|
| Dogs | 3 | 2018 | 306 | 0.090 |
Why?
|
| Blotting, Southern | 2 | 2011 | 52 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2010 | 74 | 0.080 |
Why?
|
| Carcinoma | 1 | 2010 | 117 | 0.080 |
Why?
|
| Middle Aged | 2 | 2018 | 16402 | 0.080 |
Why?
|
| Blood Platelets | 2 | 2022 | 101 | 0.080 |
Why?
|
| Models, Biological | 1 | 2014 | 1141 | 0.080 |
Why?
|
| Fibroblasts | 1 | 2011 | 370 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2009 | 130 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 1225 | 0.080 |
Why?
|
| Child | 1 | 2018 | 4324 | 0.080 |
Why?
|
| Cell Movement | 1 | 2010 | 424 | 0.080 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 472 | 0.080 |
Why?
|
| Ultraviolet Rays | 2 | 2007 | 125 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 131 | 0.070 |
Why?
|
| Primates | 2 | 2019 | 42 | 0.070 |
Why?
|
| Transfection | 2 | 2011 | 675 | 0.070 |
Why?
|
| Wound Healing | 1 | 2009 | 177 | 0.070 |
Why?
|
| Cyclobutanes | 1 | 2007 | 2 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 1128 | 0.070 |
Why?
|
| Mutagenesis | 1 | 2007 | 130 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5205 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2014 | 3110 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 647 | 0.070 |
Why?
|
| Benzylamines | 2 | 2018 | 30 | 0.070 |
Why?
|
| Binding Sites | 1 | 2009 | 870 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2009 | 376 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1975 | 0.070 |
Why?
|
| Transplantation, Autologous | 2 | 2017 | 118 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 3207 | 0.070 |
Why?
|
| DNA | 2 | 2014 | 793 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 525 | 0.060 |
Why?
|
| Transcriptome | 2 | 2020 | 334 | 0.060 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2005 | 26 | 0.060 |
Why?
|
| Receptors, Interleukin | 1 | 2005 | 36 | 0.060 |
Why?
|
| Base Pair Mismatch | 1 | 2005 | 36 | 0.060 |
Why?
|
| Xenopus | 1 | 2005 | 54 | 0.060 |
Why?
|
| Hematopoiesis | 2 | 2016 | 123 | 0.060 |
Why?
|
| Circular Dichroism | 1 | 2005 | 107 | 0.060 |
Why?
|
| Dimerization | 1 | 2005 | 146 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2016 | 942 | 0.060 |
Why?
|
| Stem Cell Factor | 1 | 2004 | 26 | 0.060 |
Why?
|
| Protein Binding | 1 | 2009 | 1559 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2005 | 293 | 0.060 |
Why?
|
| Lung | 1 | 2009 | 838 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2005 | 364 | 0.060 |
Why?
|
| Time Factors | 2 | 2016 | 3590 | 0.060 |
Why?
|
| Oocytes | 1 | 2005 | 192 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 137 | 0.050 |
Why?
|
| Cell Survival | 1 | 2005 | 557 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 798 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 1539 | 0.050 |
Why?
|
| Genome | 1 | 2005 | 253 | 0.050 |
Why?
|
| Disease Progression | 1 | 2007 | 1052 | 0.050 |
Why?
|
| Factor VIII | 1 | 2022 | 32 | 0.050 |
Why?
|
| Stem Cell Transplantation | 2 | 2014 | 75 | 0.050 |
Why?
|
| Virus Internalization | 2 | 2014 | 99 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1098 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 100 | 0.050 |
Why?
|
| Macaca | 2 | 2012 | 30 | 0.050 |
Why?
|
| RNA Interference | 1 | 2005 | 591 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2005 | 603 | 0.050 |
Why?
|
| Regenerative Medicine | 2 | 2011 | 18 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 397 | 0.050 |
Why?
|
| Clonal Selection, Antigen-Mediated | 1 | 2020 | 5 | 0.040 |
Why?
|
| Thy-1 Antigens | 1 | 2019 | 21 | 0.040 |
Why?
|
| Lysosomal Storage Diseases | 1 | 2019 | 14 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2015 | 2099 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 165 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 155 | 0.040 |
Why?
|
| Phosphoglycerate Kinase | 1 | 2018 | 1 | 0.040 |
Why?
|
| Cell Count | 1 | 2018 | 129 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2018 | 16 | 0.040 |
Why?
|
| Endosomes | 1 | 2019 | 169 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2018 | 47 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2019 | 248 | 0.040 |
Why?
|
| Protein Transport | 1 | 2019 | 394 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 280 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 1559 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 735 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2018 | 54 | 0.040 |
Why?
|
| AIDS Vaccines | 1 | 2018 | 67 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 857 | 0.040 |
Why?
|
| Clone Cells | 1 | 2017 | 106 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2018 | 122 | 0.040 |
Why?
|
| Adult | 1 | 2014 | 15882 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 641 | 0.040 |
Why?
|
| Mutation | 1 | 2005 | 2464 | 0.030 |
Why?
|
| Cell Division | 1 | 2018 | 443 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 303 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 343 | 0.030 |
Why?
|
| beta-Globins | 1 | 2015 | 9 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1231 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 60 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2015 | 12 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 351 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 94 | 0.030 |
Why?
|
| Stem Cell Research | 1 | 2014 | 2 | 0.030 |
Why?
|
| Genetic Research | 1 | 2014 | 9 | 0.030 |
Why?
|
| Education, Continuing | 1 | 2014 | 24 | 0.030 |
Why?
|
| Blood Cells | 1 | 2014 | 17 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 619 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2015 | 132 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 148 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 1154 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 115 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2014 | 113 | 0.030 |
Why?
|
| Macrophages | 1 | 2019 | 1011 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 707 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2012 | 8 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 24 | 0.030 |
Why?
|
| Purines | 1 | 2012 | 38 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2012 | 44 | 0.030 |
Why?
|
| Scorpion Venoms | 1 | 2012 | 3 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2012 | 91 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 807 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 192 | 0.020 |
Why?
|
| Electric Stimulation Therapy | 1 | 2012 | 29 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2012 | 193 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 449 | 0.020 |
Why?
|
| Gammaretrovirus | 1 | 2011 | 7 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 596 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2011 | 92 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2011 | 20 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 58 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2011 | 48 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2011 | 74 | 0.020 |
Why?
|
| Papio | 1 | 2010 | 13 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 178 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2010 | 38 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2011 | 385 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 221 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 159 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2010 | 24 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2011 | 99 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 260 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 374 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 223 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 196 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 454 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 244 | 0.020 |
Why?
|
| Glioma | 1 | 2010 | 102 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 354 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1989 | 135 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1989 | 194 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2007 | 2 | 0.020 |
Why?
|
| Globins | 1 | 2007 | 24 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 324 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 848 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 854 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 13463 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1989 | 5 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1989 | 42 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1989 | 52 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1989 | 285 | 0.000 |
Why?
|
| Cricetinae | 1 | 1989 | 376 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1989 | 453 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1989 | 696 | 0.000 |
Why?
|